AMANDA SAVOLT: Open Payments
NPI 1659058188 · LAKEWOOD, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$708 in 33 payments from 14 companies in 2025. Trend: 2023 $180 · 2024 $1,896 · 2025 $708
Food & beverage: $708
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 13 | $278 |
| GENZYME CORPORATION | 4 | $62 |
| GlaxoSmithKline, LLC. | 2 | $56 |
| Regeneron Healthcare Solutions, Inc. | 3 | $53 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $40 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $33 |
| Grifols USA, LLC | 2 | $29 |
| Verona Pharma, Inc. | 1 | $29 |
| Insmed, Inc. | 1 | $26 |
| Actelion Pharmaceuticals US, Inc. | 1 | $25 |
Products named: TEZSPIRE, DUPIXENT, FASENRA, TRELEGY ELLIPTA, LUMRYZ, BREZTRI, OFEV, Prolastin-C Liquid.
Industry payments across CO — which companies pay providers there.
